A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions
顯示簡易詮釋資料 統計資料| 欄位 | 內容 | 語言 |
|---|---|---|
dc.citation.volume |
9 | en_US |
dc.citation.woscount |
0 | en_US |
dc.contributor.author |
Lin, Tony Eight | en_US |
dc.contributor.author |
HuangFu, Wei-Chun | en_US |
dc.contributor.author |
Chao, Min-Wu | en_US |
dc.contributor.author |
Sung, Tzu-Ying | en_US |
dc.contributor.author |
Chang, Chao-Di | en_US |
dc.contributor.author |
Chen, Yi-Ying | en_US |
dc.contributor.author |
Hsieh, Jui-Hua | en_US |
dc.contributor.author |
Tu, Huang-Ju | en_US |
dc.contributor.author |
Huang, Han-Li | en_US |
dc.contributor.author |
Pan, Shiow-Lin | en_US |
dc.contributor.author |
Hsu, Kai-Cheng | en_US |
dc.contributor.department |
生物資訊及系統生物研究所 | zh_TW |
dc.contributor.department |
Institude of Bioinformatics and Systems Biology | en_US |
dc.date.accessioned |
2019-04-02T05:57:53Z | |
dc.date.available |
2019-04-02T05:57:53Z | |
dc.date.issued |
2018-12-04 | en_US |
dc.description.abstract |
The JAK2/STAT signaling pathway mediates cytokine receptor signals that are involved in cell growth, survival and homeostasis. JAK2 is a member of the Janus kinase (JAK) family and aberrant JAK2/STAT is involved with various diseases, making the pathway a therapeutic target. The similarity between the ATP binding site of protein kinases has made development of specific inhibitors difficult. Current JAK2 inhibitors are not selective and produce unwanted side effects. It is thought that increasing selectivity of kinase inhibitors may reduce the side effects seen with current treatment options. Thus, there is a great need for a selective JAK inhibitor. In this study, we identified a JAK2 specific inhibitor. We first identified key pharmacological interactions in the JAK2 binding site by analyzing known JAK2 inhibitors. Then, we performed structure-based virtual screening and filtered compounds based on their pharmacological interactions and identified compound NSC13626 as a potential JAK2 inhibitor. Results of enzymatic assays revealed that against a panel of kinases, compound NSC13626 is a JAK2 inhibitor and has high selectivity toward the JAK2 and JAK3 isozymes. Our cellular assays revealed that compound NSC13626 inhibits colorectal cancer cell (CRC) growth by downregulating phosphorylation of STAT3 and arresting the cell cycle in the S phase. Thus, we believe that compound NSC13626 has potential to be further optimized as a selective JAK2 drug. | en_US |
dc.identifier.doi |
10.3389/fphar.2018.01379 | en_US |
dc.identifier.issn |
1663-9812 | en_US |
dc.identifier.journal |
FRONTIERS IN PHARMACOLOGY | en_US |
dc.identifier.uri |
http://dx.doi.org/10.3389/fphar.2018.01379 | en_US |
dc.identifier.uri |
https://ir.lib.nycu.edu.tw/handle/11536/148558 | |
dc.identifier.wosnumber |
WOS:000452050800001 | en_US |
dc.language.iso |
en_US | en_US |
dc.subject |
selective inhibitor | en_US |
dc.subject |
JAK2 | en_US |
dc.subject |
virtual screening | en_US |
dc.subject |
docking | en_US |
dc.subject |
pharmacological interaction | en_US |
dc.title |
A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions | en_US |
dc.type |
Article | en_US |
檔案
本條目沒有附加檔案。
所屬典藏: 期刊論文
引用此條目
Lin, T. E., HuangFu, W.-C., Chao, M.-W., Sung, T.-Y., Chang, C.-D., Chen, Y.-Y., Hsieh, J.-H., Tu, H.-J., Huang, H.-L., Pan, S.-L., & Hsu, K.-C. (2018). A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions. FRONTIERS IN PHARMACOLOGY, 9. https://doi.org/10.3389/fphar.2018.01379
引用文字依 APA 第 7 版格式自動產生,使用前請再核對。
分享
永久網址:https://ir.lib.nycu.edu.tw/handle/11536/148558